Want to join the conversation?
Joshua Jennings of Cowen & Co. asks about biosimilar competition to the REMICADE franchise in 2017 and beyond. $JNJ CFO Dominic Caruso said the company does not expect biosimilar competition in 2016. $JNJ has several patents that it intends to defend. Overall, the immunology franchise is very strong and remain comfortable with the growth outlook.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.